Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$1.44 and traded as high as C$1.64. Oncolytics Biotech shares last traded at C$1.59, with a volume of 50,418 shares trading hands.
Wall Street Analyst Weigh In
Separately, Raymond James raised their price target on Oncolytics Biotech from C$3.00 to C$3.50 in a report on Friday, September 20th.
Read Our Latest Analysis on Oncolytics Biotech
Oncolytics Biotech Trading Up 4.4 %
The firm has a market cap of C$127.59 million, a PE ratio of -4.29 and a beta of 1.35. The company has a debt-to-equity ratio of 6.09, a quick ratio of 8.86 and a current ratio of 4.99. The company has a 50 day simple moving average of C$1.45 and a two-hundred day simple moving average of C$1.44.
Oncolytics Biotech (TSE:ONC - Get Free Report) last posted its quarterly earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of C($0.10). Analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.
Oncolytics Biotech Company Profile
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
See Also
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
